Q-vaxcelerate: A distributed development approach for a new Coxiella burnetii vaccine

References

• Leblanc P, Moise L, Luza C, Chantaralawan K, Lezeau L, Yuan J, Field M, Richer D, Boyle C, Martin WD, et al. VaxCelerate II: Rapid development of a self- assembling vaccine for Lassa fever VaxCelerate II: Rapid development of a self-assembling vaccine for Lassa fever. 2014;5515(October 2016):1-17.
   Google Scholar
• Derrick EH. “Q” fever, a new fever entity: clinical features, diagnosis and laboratory investigation. Rev Infect Dis. 1983;5(4):790-800. doi:10.1093/clinids/5.4.790. PMID:6622891
   PubMedGoogle Scholar
• Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12(4):518-553. PMID:10515901
   PubMed Web of Science ®Google Scholar
• Dijkstra F, Riphagen-Dalhuisen J, Wijers N, Hak E, Van der Sande MAB, Morroy G, Schneeberger PM, Schimmer B, Notermans DW, Van der Hoek W. Antibiotic therapy for acute Q fever in The Netherlands in 2007 and 2008 and its relation to hospitalization. Epidemiol Infect. 2011;139(9):1332-1341. doi:10.1017/S0950268810002621. PMID:21087542
   PubMed Web of Science ®Google Scholar
• Parker NR, Barralet JH, Bell AM. Seminar Q fever. Lancet. 2006;367:679-688. doi:10.1016/S0140-6736(06)68266-4. PMID:16503466
   PubMed Web of Science ®Google Scholar
• Million M, Raoult D. No Such Thing as Chronic Q Fever. Emerg Infect Dis. 2017;23(5):856-857. doi:10.3201/eid2305.151159. PMID:28418317
   PubMed Web of Science ®Google Scholar
• Kazar J, Brezina R, Palanova A, Tvrdá B, Schramek S. Immunogenicity and reactogenicity of a Q fever chemovaccine in persons professionally exposed to Q fever in Czechoslovakia. Bull World Health Organ. 1982;60(3):389-394. PMID:6982774
   PubMed Web of Science ®Google Scholar
• Waag DM, England MJ, Bolt CR, Williams JC. Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii. Clin Vaccine Immunol. 2008;15(10):1505-1512. doi:10.1128/CVI.00119-08. PMID:18701647
   PubMed Web of Science ®Google Scholar
• Biotherapies CSL, Road P. A guide to Q fever and Q fever vaccination. Marmion B, Spelman D, eds. Med J Aust. 2009 Parkville, ABN 66120398067.
   Google Scholar
• Wielders CCH, Wuister AMH, De Visser VL, De Jager-Leclercq MG, Groot CAR, Dijkstra F, et al. Characteristics of hospitalized acute Q fever patients during a large epidemic, the Netherlands. PLoS One. 2014;9(3). PMID:24614585
   PubMed Web of Science ®Google Scholar
• Madariaga MG, Rezai K, Trenholme GM, Weinstein RA. Q fever: A biological weapon in your backyard. Lancet Infect Dis. 2003;3(11):709-721. doi:10.1016/S1473-3099(03)00804-1. PMID:14592601
   PubMed Web of Science ®Google Scholar
• Andoh M, Zhang G, Russell-Lodrigue KE, Shive HR, Weeks BR, Samuel JE. T cells are essential for bacterial clearance, and gamma interferon, tumor necrosis factor alpha, and B cells are crucial for disease development in Coxiella burnetii infection in mice. Infect Immun. 2007;75(7):3245-3255. PMID:17438029
   PubMed Web of Science ®Google Scholar
• Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, VerBerkmoes NC, Sztein MB, Losikoff PT, Martin WD, et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother. 2013;9(7):1577-1586. doi:10.4161/hv.24615. PMID:23584251
   PubMed Web of Science ®Google Scholar
• Moise L, Gutierrez A, Kibria F, Martin R, Tassone R, Liu R, Terry F, Martin B, De Groot AS. iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines. Hum Vaccin Immunother. 2015;11(9):2312-2321. doi:10.1080/21645515.2015.1061159. PMID:26155959
   PubMed Web of Science ®Google Scholar
• Schoffelen T, Limonard GJ, Bleeker-Rovers CP, Bouwman JJ, van der Meer JW, Nabuurs-Franssen M, et al. Diagnosis of Coxiella burnetii infection: comparison of a whole blood interferon-gamma production assay and a Coxiella ELISPOT. PLoS One. 2014;9(8):e103749. doi:10.1371/journal.pone.0103749. PMID:25084353
   PubMed Web of Science ®Google Scholar
• Limonard GJM, Peters JB, Besselink R, Groot CAR, Dekhuijzen PNR, Vercoulen JH, Nabuurs-Franssen MH. Persistence of impaired health status of Q fever patients 4 years after the first Dutch outbreak. Epidemiol Infect. 2016;144(6):1142-1147. doi:10.1017/S0950268815002216. PMID:26508155
   PubMed Web of Science ®Google Scholar
• Morroy G, Van Der Hoek W, Nanver ZD, Schneeberger PM, Bleeker-Rovers CP, Van Der Velden J, Coutinho RA. The health status of a village population, 7 years after a major Q fever outbreak. Epidemiol Infect. 2016;144(6):1153-1162. doi:10.1017/S0950268815002472. PMID:26560803
   PubMed Web of Science ®Google Scholar
• Wilhelmsen CL, Waag DM. Guinea pig abscess/hypersensitivity model for study of adverse vaccination reactions induced by use of Q fever vaccines. Comp Med. 2000;50(4):374-378. PMID:11020154
   PubMed Web of Science ®Google Scholar
• Scott GH, Williams JC, Stephenson EH. Animal models in Q fever: pathological responses of inbred mice to phase I Coxiella burnetii. J Gen Microbiol. 1987;133(3):691-700. PMID:3655728
   PubMedGoogle Scholar
• Chen C, Dow C, Wang P, Sidney J, Read A, Harmsen A, Samuel JE, Peters B. Identification of CD4+ T cell epitopes in C. burnetii antigens targeted by antibody responses. PLoS One. 2011;6(3):e17712. doi:10.1371/journal.pone.0017712. PMID:21423609
   PubMed Web of Science ®Google Scholar
• Zhang G, Peng Y, Schoenlaub L, Elliott A, Mitchell W, Zhang Y. Formalin-inactivated coxiella burnetii phase i vaccine-induced protection depends on b cells to produce protective igm and igg. Infect Immun. 2013;81(6):2112-2122. PMID:23545296
   PubMed Web of Science ®Google Scholar
• Li W, Joshi M, Singhania S, Ramsey K, Murthy A. Peptide vaccine: progress and challenges. Vaccines. 2014;2(3):515-536. doi:10.3390/vaccines2030515. PMID:26344743
   PubMedGoogle Scholar
• Martin SD, Brown SD, Wick DA, Nielsen JS, Kroeger DR, Twumasi-Boateng K, Holt RA, Nelson BH. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS One. 2016;11(5):1-22. doi:10.1371/journal.pone.0155189
   Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72(5):1081-1091. doi:10.1158/0008-5472.CAN-11-3722. PMID:22237626
   PubMed Web of Science ®Google Scholar
• Lin S, Cheng C-W, Su E. Prediction of B-cell epitopes using evolutionary information and propensity scales. BMC Bioinformatics. 2013;14(Suppl 2):S10. doi:10.1186/1471-2105-14-S2-S10. PMID:23484214
   PubMed Web of Science ®Google Scholar
• Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, Rosales-Mendoza S. An overview of bioinformatics tools for epitope prediction: Implications on vaccine development. J Biomed Inform. 2015;53:405-414. doi:10.1016/j.jbi.2014.11.003. PMID:25464113
   PubMed Web of Science ®Google Scholar
• Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: Application to the MHC class i system. Bioinformatics. 2015;32(4):511-517. doi:10.1093/bioinformatics/btv639. PMID:26515819
   PubMed Web of Science ®Google Scholar
• Nielsen M, Lundegaard C, Worning P, Lauemøller SL, Lamberth K, Buus S, Brunak S, Lund O. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 2003;12(5):1007-1017. doi:10.1110/ps.0239403. PMID:12717023
   PubMed Web of Science ®Google Scholar
• Messitt TJ, Terry F, Moise L, Martin W, De Groot AS. A comparison of two methods for T cell epitope mapping: “cell free” in vitro versus immunoinformatics. Immunome Res. 2011;7(2):1577-1586. doi:10.4172/1745-7580.1000045
   Google Scholar